NKGen Biotech, Inc.
NKGN evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $7.8M
- Lead Asset:
- snk01 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for NKGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 1 clinical trial for NKGen Biotech, Inc..
Run NKGen Biotech, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NKGen Biotech, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$193K
| Holder | Shares | Value |
|---|---|---|
| meteora capital, llc | 2,755,935 | $193K |
Short Interest
as of May 21, 2026- % of float
- 5.5%
- Days to cover
- 0.4
- Shares short
- 1,506,310
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NKGN short interestGovernance
Frequently asked questions
What is NKGen Biotech, Inc.'s lead drug candidate?
NKGen Biotech, Inc.'s most advanced tracked candidate is snk01 (Phase 1/Phase 2) for Moderate Alzheimer Disease; Alzheimer Disease.
Who is the CEO of NKGen Biotech, Inc.?
Dr. Paul Y. Song M.D. is the chief executive officer of NKGen Biotech, Inc. (NKGN).
Where is NKGen Biotech, Inc. headquartered?
NKGen Biotech, Inc. (NKGN) is headquartered in Santa Ana, CA, United States.
What therapeutic areas does NKGen Biotech, Inc. focus on?
NKGen Biotech, Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.